Abbvie Inc. vs Novartis AG
ABBV vs NVS — side-by-side comparison from reported financials. ABBV leads 4, NVS leads 8 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
| Metric | ABBV | NVS |
|---|---|---|
| Price | $276.43 | $143.75 |
| Market cap | $488B | $273B |
| Revenue (TTM) | $64.4B | $56.7B |
| Revenue growth | +1.8% | +9.1% |
| Net margin | 9.8% | 24.7% |
| Free cash flow | $18.2B | $16.8B |
| Net cash (debt) | ($56.2B) | ($41.4B) |
| 1-year price return | +19.8% | +9.7% |
| P/E | 77.4 | 20.3 |
| P/E vs own history (cheap-side %) | 23% | 46% |
| Dividend yield | 2.45% | 3.49% |
| Return on equity | 96% | 30% |
| Altman Z-score | 2.33 | 3.50 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 57,000 | 75,267 |
Full résumé-style profiles: ABBV CV · NVS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.